The AMA Treaty ratification will strengthen the country’s national positioning as a pharmaceutical, health products and technologies investment destination.
The Kenya Health Federation (KHF) has welcomed the cabinet’s approval to ratify the African Medicines Agency (AMA) Treaty.
On Thursday, the cabinet chaired by President Uhuru Kenyatta approved the ratification of the African Union Treaty for the Establishment of the African Medicines Agency (AMA), which now awaits the passing of the necessary legislative instruments at the National Assembly.
Speaking when he confirmed KHF’s support for the ratification of the AMA instrument, the federation's chairperson Dr Kanyenje Gakombe said local health stakeholders would provide the necessary support to the government in the race towards the establishment of AMA headquarters in Kenya.
AMA is an African Continental Agency that contributes to the improved regulation of medicines, medical products and technologies and to advance the implementation of the Pharmaceutical Manufacturing Plan of Africa.
The establishment of AMA in Kenya, he said, will provide the country with an opportunity to leverage foreign direct investment flows estimated at more than Sh 570 billion in the short-to-medium term.
The establishment of AMA locally, Dr Gakombe said, will enhance the country’s national competitiveness as a healthcare and pharmaceutical manufacturing hub in sub-Sahara Africa.
He noted that the AMA Treaty ratification will strengthen the country’s national positioning as a pharmaceutical, health products and technologies investment destination.
“KHF, which is the Health Sector Board of the Kenya Private Sector Alliance (KEPSA), salutes the cabinet and the Ministry of Health for moving a step further towards the signing and ratification of the AMA Treaty,” Dr Gakombe said.
“We now humbly request our Members of Parliament to prioritise the passing of the legislative instruments to boost further our chance of hosting the AMA in Kenya. The support of Health Cabinet Secretary Mutahi Kagwe and his officers in this journey has been immense and commendable,” he added.
Based on the recent securing of a $500 million investment commitment by pharmaceutical biotechnology firm Moderna seeking to set up a manufacturing plant in Kenya, KHF estimates that the hosting of AMA in Kenya will ignite a tenfold commitment to similar investments.
“Kenya is currently well placed and resourced intellectually to act as the AMA host site of choice. The recent commitment by Moderna is a good example, and we have a good chance to scale up the commitments ten times if we push and lobby for the hosting of AMA in Kenya,” Dr Gakombe said
He further noted that the hosting of AMA in Kenya and the proposed setting up of the Moderna manufacturing plant would provide immense social and economic benefits, including quality job creation, while securing our national competitiveness as the home of big pharma in Africa.
“We are confident that these two opportunities; Moderna Manufacturing Facility and AMA, present huge benefits for our country and its citizens, which include, among others; sustainable supply chains, technology transfer, knowledge transfer, skills transfer, manufacture of complex and more advanced medicines and economic empowerment through the creation of new quality jobs and export opportunities,” he said.
The AMA Treaty entered into force on 5th November 2021 upon depositing the 15th Instrument of ratification at the African Union Commission.
This will further cement the Business Case for Kenya as a hub for high quality and affordable health products and health technologies.
This also will help the country emerge as a hub for quality healthcare provision and delivery attracting investments in biopharmaceuticals, vaccines, related medical products and infrastructure.